MedElevator
Войти в исследования Arthritis care and research : the official journal of the Arthritis Health Professions Association · 2000
The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Klein-Gitelman M S, Waters T, Pachman L M
Аннотация
OBJECTIVE: To perform a cost-identification and cost-effectiveness analysis comparing oral corticosteroids (OCS) with high-dose intermittent intravenous corticosteroid (IVCS) regimens in the treatment of juvenile dermatomyositis (JDM).
METHODS: Children previously diagnosed and treated for JDM (without myositis-specific or myositis-associated autoantibodies) at a single medical center by a single provider were identified. Two treatment protocols were compared: OCS and IVCS. Data on initial disease severity, time to remission, resource use, and costs generated were collected from patient records. Incremental cost-effectiveness ratios (ICE) were constructed.
RESULTS: Patients treated with IVCS achieved median remission 2 years earlier at median increased cost of $13,736. The ICE ratio comparing IVCS to OCS is $6,868 per year of disease avoided.
CONCLUSION: This study suggests that, although IVCS treatments are costly, they are cost-effective.
METHODS: Children previously diagnosed and treated for JDM (without myositis-specific or myositis-associated autoantibodies) at a single medical center by a single provider were identified. Two treatment protocols were compared: OCS and IVCS. Data on initial disease severity, time to remission, resource use, and costs generated were collected from patient records. Incremental cost-effectiveness ratios (ICE) were constructed.
RESULTS: Patients treated with IVCS achieved median remission 2 years earlier at median increased cost of $13,736. The ICE ratio comparing IVCS to OCS is $6,868 per year of disease avoided.
CONCLUSION: This study suggests that, although IVCS treatments are costly, they are cost-effective.
Предметные рубрики MeSH
Administration, OralAdrenal Cortex HormonesChicagoChild, PreschoolCost SavingsCost of IllnessCost-Benefit AnalysisDermatomyositisDirect Service CostsDrug CostsFemaleHealth ResourcesHospital CostsHospitals, PediatricHumansInfusions, IntravenousLength of StayMaleRemission InductionRetrospective StudiesTime FactorsTreatment Outcome